Lirum Therapeutics Inc. has presented data regarding their insulin-like growth factor receptor (IGF-1R) antagonist LX-101, which couples an IGF-1 variant to a cytotoxic methotrexate payload. The antitumoral activity of LX-101 was investigated in Ewing sarcoma and desmoplastic small round cell tumor.
Tharimmune Inc. has applied its Epiclick multispecific antibody engineering platform to expand its pipeline. With Epiclick, the company can combine distinct antibody binding domains, including those derived from previously inaccessible and undruggable epitopes, in either small-format or full-length configurations to target hard-to-reach epitopes.
Researchers from Ileadbms Co. Ltd. presented the discovery and preclinical characterization of IL-21120033, a new CXCR7 agonist being developed for the treatment of inflammatory bowel disease.
Combining the direct cytotoxic effects of antibody-drug conjugates (ADCs) with the immune-enhancing properties of immunostimulators represents a new therapeutic strategy that could not only eradicate tumor cells, but also reprogram the tumor microenvironment, leading to durable and systemic anticancer immunity. Using this new approach, researchers from Bioray Pharmaceutical Co. Ltd. developed and characterized of a new dual drug ADC (BiADC), named BR-113, designed to target human (h)Trop2.
Neurenati Therapeutics Inc.’s NEU-001 has been awarded U.S. orphan drug and rare pediatric disease designations by the FDA for the treatment of Hirschsprung disease.
Centauri Therapeutics Ltd. has selected its first clinical candidate in the ABX-01 program to treat gram-negative bacterial lung infections. Based on the company’s Alphamer platform, the broad-spectrum antimicrobial peptide has been selected to treat clinically prevalent and multidrug-resistant bacterial strains.
Jnana Therapeutics Inc. has described sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of diabetes, chronic kidney disease, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), phenylketonuria, metabolic syndrome, obesity, neurodevelopmental disorders and autism spectrum disorders, among others.
Xenon Pharmaceuticals Inc. has divulged potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators reported to be useful for the treatment of pain, anhedonia, depression and seizure disorders.
Raythera Inc. has identified TNF-α modulators reported to be useful for the treatment of inflammatory disorders, autoimmune disease, neurological disorders, pain, cardiovascular disorders, cancer, metabolic disorders and eye disorders.
Virginia Commonwealth University has synthesized nitrogen-walk derivatives of NAN acting as µ-opioid receptor modulators reported to be useful for the treatment of pain, opioid dependency and neurological disorders.
RSS
